ArticleThe oncologist2025

Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant CPI in BRAF V600-mutated stage III/IV melanoma.

Jeffrey Weber et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.